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Simple Summary: The resistance of cancer cells to cytotoxic chemotherapy limits cure rates in breast
cancer, and a better understanding of resistance mechanisms will aid design of strategies to improve
treatments. We have identified molecules that cause chemoresistance through comparison of matched
breast cancer samples from before and after chemotherapy treatment, and by manipulating their
levels in cultured breast cancer cells and measuring chemotherapy-induced cell death. We show that
microRNA-195 and microRNA-26b induce resistance to chemotherapy in breast cancer by reducing
the levels of the protein SEMA6D. Accordingly, levels of SEMA6D in breast cancers predict the
survival of patients after chemotherapy. SEMA6D is a predictive marker and SEMA6D signaling
presents a therapeutic opportunity for sensitizing cells to chemotherapy.
Abstract: Background: poor prognosis primary breast cancers are typically treated with cytotoxic
chemotherapy. However, recurrences remain relatively common even after this aggressive therapy.
Comparison of matched tumours pre- and post-chemotherapy can allow identification of molecular
characteristics of therapy resistance and thereby potentially aid discovery of novel predictive markers
or targets for chemosensitisation. Through this comparison, we aimed to identify microRNAs
associated with chemoresistance, define microRNA target genes, and assess targets as predictors of
chemotherapy response. Methods: cancer cells were laser microdissected from matched breast cancer
tissues pre- and post-chemotherapy from estrogen receptor positive/HER2 negative breast cancers
showing partial responses to epirubicin/cyclophosphamide chemotherapy (n = 5). MicroRNA
expression was profiled using qPCR arrays. MicroRNA/mRNA expression was manipulated in
estrogen receptor positive/HER2 negative breast cancer cell lines (MCF7 and MDA-MB-175 cells)
with mimics, inhibitors or siRNAs, and chemoresponse was assessed using MTT and colony forming
survival assays. MicroRNA targets were identified by RNA-sequencing of microRNA mimic pull-
downs, and comparison of these with mRNAs containing predicted microRNA binding sites. Survival
correlations were tested using the METABRIC expression dataset (n = 1979). Results: miR-195 and
miR-26b were consistently up-regulated after therapy, and changes in their expression in cell lines
caused significant differences in chemotherapy sensitivity, in accordance with up-regulation driving
resistance. SEMA6D was defined and confirmed as a target of the microRNAs. Reduced SEMA6D
expression was significantly associated with chemoresistance, in accordance with SEMA6D being
a down-stream effector of the microRNAs. Finally, low SEMA6D expression in breast cancers
was significantly associated with poor survival after chemotherapy, but not after other therapies.
Conclusions: microRNAs and their targets influence chemoresponse, allowing the identification of
SEMA6D as a predictive marker for chemotherapy response that could be used to direct therapy or
as a target in chemosensitisation strategies.
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1. Introduction
Cytotoxic chemotherapy is a component of treatment for around a third of primary
breast cancers, comprising those associated with relatively poor prognoses such as larger,
lymph node positive, HER2-positive, or triple-negative tumours [1]. It is worth empha-
sizing that this treatment is therefore used in at least some cases of each of the classic
molecular subtypes of breast cancer [2], including luminal subtypes (in the larger, high
grade, node-positive or HER2 positive cases), the HER2-enriched subtype (in combination
with HER2-targetting therapies), and the triple negatives (for which there are currently no
alternative systemic treatments in the primary setting). Unfortunately, treatment failure
in the form of cancer recurrences is relatively common in these groups, even after this ag-
gressive therapy, and identification of chemotherapy resistance mechanisms is required to
improve cancer outcomes [3]. Chemotherapy has traditionally been used in primary breast
cancer in the adjuvant setting (after surgery). Alternatively, neoadjuvant (before surgery)
chemotherapy is being increasingly used since it can down-stage tumours, thereby facilitat-
ing breast-conserving surgery in cases that would otherwise require mastectomies [4], and
also allow opportunities for switching regimens if responses are poor, as assessed by longi-
tudinal imaging [5]. From a research perspective, neoadjuvant chemotherapy provides the
further advantage that matched tumour tissue from pre- and post-therapy can be available,
allowing for the comparative identification of the therapy-associated changes within the
cancer cells that may be associated with relative chemotherapy resistance. This strategy
has been used successfully by our team and others, to identify chemoresponse-associated
somatic mutations [6–8], and changes in protein [9,10] or mRNA expression [8,11]. MicroR-
NAs have received less attention in this context, with only a total of five previous studies
following this design [12–16], leading to identification of only one microRNA, miR-18a, as
a potential mediator of chemoresistance [13].
One key issue for these findings is that the cellular composition of breast cancer
tissues changes dramatically after neoadjuvant therapy; post-therapy tissues are often
fibrotic, with reduced representation of cancer cells [17,18] and reduced lymphocyte in-
filtration [19,20]. Therefore, the discovery of potential cancer cell autonomous resistance
mechanisms through comparisons of whole tissue samples from pre- and post-therapy
can be confounded by differences in tissue composition. This issue has previously been
addressed by the exclusion of mRNAs for stromal-associated genes from any findings [11].
However, this approach is particularly problematic for microRNA analysis since data
concerning which microRNAs could be regarded as stromal-specific are lacking. In order
to circumvent this problem, we have previously performed laser microdissection to purify
and enrich cancer cells from both matched samples, thereby allowing their more effective
comparison [6,7]. We are aware of only one other study in which laser microdissection was
carried out in the context of pre- and post-chemotherapy comparisons in breast cancer, in
which mRNA expression profiles were compared before and after therapy [21], although it
should be noted that only the post-therapy samples were laser microdissected.
Here, we have studied changes in expression of microRNAs after neoadjuvant chemo-
therapy in cancer cells, employing for the first-time laser microdissection to focus on the
selection of potential resistance characteristics within these cells. For the discovery phase
of our work, we have focused on estrogen receptor positive/HER2 negative cancers. This
was because these cancers typically have a less than complete response to neoadjuvant
chemotherapy [22], thereby increasing the cancer cell content of the post-therapy samples.
Through this, we identified and then validate two microRNAs and a microRNA-target that
confer chemoresistance in breast cancer cells, using cell lines representative of estrogen
receptor positive/HER2 negative cancers. Subsequently, we assessed the impact of this mi-
croRNA target, SEMA6D, on patient outcomes, specifically after chemotherapy, in a cohort
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containing all the diversity of breast cancer subtypes that are treated with chemotherapy,
demonstrating its applicability to this treatment modality beyond the estrogen receptor
positive/HER2 negative subtype used for discovery.
2. Materials and Methods
2.1. Ethics, Patients and Tissue Samples
Ethical approval was obtained from Leeds (East) REC (ref 06/Q1206/180). Patients
included were diagnosed within LTH NHS Trust (Leeds, UK) with estrogen receptor (ER)
positive/HER2 negative primary invasive ductal breast carcinoma and were treated with 6
cycles of neoadjuvant epirubicin/cyclophosphamide, showing partial treatment resistance
as determined by longitudinal MRI imaging and histopathology assessments of resections
(partial treatment resistance was defined here as failing to achieve a complete pathological
response, but evidence of some cell killing from reduction in tumour size on MRI scans).
Patients were aged from 41 to 64 at diagnosis (mean 51) and tumours were grade 1 (1 case),
2 (2 cases) or 3 (2 cases); a table of clinico-pathological data on a patient-by-patient basis is
shown in Table S1. Formalin-fixed, paraffin-embedded tumour tissue blocks were available
representing matched diagnostic core biopsies (pre-therapy) and resections (post-therapy).
2.2. Laser Capture Microdissection, RNA Extraction and microRNA (miRNA) Profiling
Tumour tissue was sectioned and prepared, and epithelial cancer cells were isolated
using a Zeiss/PALM machine (Zeiss; Oberkochen, Germany) or ArcturusXT System (Ther-
moFisher; Waltham, MA, USA) as previously described [7]. RNA was extracted from
cells using AllPrep DNA/RNA FFPE Kits (Qiagen; Hilden, Germany) and quantified
using a NanoDrop 2000 (ThermoFisher; Waltham, MA, USA). MicroRNAs were reverse
transcribed (TaqMan MicroRNA Reverse Transcription Kit; Applied Biosystems; Carlsbad,
CA, USA) and profiled (TaqMan MicroRNA Array A card v2; catalogue number 4398965,
ThermoFisher, Waltham, MA, USA) following the manufacturer’s protocols. qPCR was
performed on the 7900HT Fast Real-Time PCR System (Applied Biosystems; Carlsbad, CA,
USA). Expression levels were normalized to the mean of all miRNAs expressed within that
sample, and relative expression was calculated by comparing post-NAC with matched
pre-NAC expression using the delta-delta Ct method [23].
2.3. Cell Culture and Transfections
MCF7 and MDA-MB-175 cells were purchased from ATCC (Manassas, VA, USA) and
cultured in DMEM and Leibovitz’s L15 (Thermofisher; Waltham, MA, USA) respectively,
supplemented with 10% FCS (Sigma; St Louis, MO, USA) and 1% penicillin/streptomycin
(final concentrations 100 U/mL and 100 µg/mL) (Thermofisher; Waltham, MA, USA). Cells
were grown at 37 ◦C in humidified 95% air/5% CO2 (MCF7) or 100% air (MDA-MB-175).
Cell line identity was confirmed (STR profiles, Leeds Genomic Service, Leeds, UK) and
cultures were consistently Mycoplasma negative (MycoAlert; Lonza; Basel, Switzerland).
MiRNA mimics, hairpin inhibitors and scrambled controls were purchased from Dharma-
con (Lafayette, LA, USA) and SEMA6D targeted (#76776117) and negative control siRNAs
were purchased from IDT (Coralville, IA, USA). Cells were seeded into 96-well plates
(MTT assays) or 24-well plates (clonogenic survival assays) and transfected at 70–80%
confluency the next day. MiRNA mimic or inhibitor mixes were prepared in serum-free
Opti-MEM, and transfection complexes prepared using Lipofectamine 2000 according to
manufacturer’s protocols (Thermofisher; Waltham, MA, USA). Transfection complexes
were added to cells in 2 volumes of Opti-MEM and one volume of standard medium.
Medium was replaced with standard medium after 24 h. Biotinylated miRCURY LNA mi-
croRNA mimics or scrambled controls were used for the pulldown assays (Exiqon; Vedbæk,
Denmark); MCF7 cells were transfected in T150 tissue culture flasks with Lipofectamine
2000 as described above. The epirubicin-resistant MCF7 line was developed by continuous
culture in normal medium supplemented with epirubicin hydrochloride (Sigma; St Louis,
MO, USA), initially at 1nM and then increasing over months to 350 nM.
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2.4. Chemoresponse Assays
Cells were treated with 30nM-1µM epirubicin hydrochloride (Sigma; St Louis, MO,
USA) for 24 h, starting 48 h post-transfection. For MTT assays, medium was removed and
replaced with 25 µL of 5 mg/mL MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazdium
Bromide) (ThermoFisher; Waltham, MA, USA) and the cells were incubated under normal
growth conditions in the dark. After 4 h, the MTT reagent was removed and the precipitates
were dissolved in 50 µL 100% isopropanol. Absorbance was assessed at 570 nm using a
Mithras LB940 plate reader (Berthold; Bad Wildbad, Germany). Clonogenic survival assays
were performed as described previously [24]. In brief, cells were transfected, treated with
epirubicin, and reseeded at low density (100 MCF7 or 200 MDA-MB-175 cells per well of
6-well plates) in technical duplicates without further epirubicin. MCF7 cells were reseeded
in fresh media while MDA-MB-175 cells were seeded in conditioned media, prepared
by being placed above the confluent MDA-MB-175 cells for 24 h and then centrifuged to
ensure no carry-over of cells. Cells were incubated undisturbed under normal growth
conditions for 14 days before colonies were stained with crystal violet (Sigma; St Louis,
MO, USA). Colonies were counted macroscopically, regarding >30 cells as a colony. To
validate colony counting reproducibility, 10 plates with varying numbers of colonies were
counted independently by the authors DEB and LMA; the scores were highly correlated
(R2 = 0.999).
2.5. Expression Analyses (qPCR, Western Blots)
For qPCR, total RNA was extracted using ReliaPrep RNA Cell Minipreps (Promega;
Madison, WI, USA) according to the manufacturer’s protocols and quantified using a
NanoDrop 2000 (Thermofisher; Waltham, MA, USA). For miRNA quantification, cDNA
was synthesized using TaqMan Reverse Transcription Kits (Applied Biosystems; Carlsbad,
CA, USA) and expression was quantified using TaqMan 2× Universal PCR Master Mix, No
AmpErase UNG, and miRNA primers (Applied Biosystems; Carlsbad, CA, USA) according
to the manufacturer’s protocols. For mRNA quantification, cDNA was synthesized using
the GoScript Reverse Transcription System and expression was quantified using GoTaq
qPCR Master Mix kits (Promega; Madison, WI, USA) according to the manufacturer’s
protocols. Analyses were performed using the 7500 or QuantStudio 5 Real Time PCR
Systems (Applied Biosystems; Carlsbad, CA, USA) in technical triplicates using standard
modes and cycling conditions. The average Ct of The technical replicates was taken for
each sample. Fold differences were calculated using the delta-delta Ct method [23], using
RNU48 and ACTB as normalizers for the miRNA and mRNA respectively. For protein
analyses, transfected cells were washed in PBS (4 ◦C) and then lysed (10 mM HEPES pH7.9,
10 mM KCl, 0.1 mM EDTA, 0.4% IGEPAL CA-630 (Sigma-Aldrich; St Louis, MO, USA),
1 mM DTT and Halt protease/phosphatase inhibitor (ThermoFisher; Waltham, MA, USA);
10 min; room temperature). Cells/buffer was centrifuged (15,000× g, 3 min, 4 ◦C) and
the supernatants were collected. Proteins were quantified by Bradford assays (Merck;
Kenilworth, NJ, USA). Samples were heated in Laemmli buffer (ThermoFisher; Waltham,
MA, USA), 5 min at 90 ◦C, to denature proteins, and equal masses were loaded into each
lane of 4–12% polyacrylamide gels (BioRad; Watford, UK). The proteins were separated,
and then transferred to PVDF and blocked with 5% non-fat milk in Tris Buffered Saline,
0.1% Tween-20 (TBST) for 45 min. Membranes were incubated with a rabbit polyclonal
antibody targeting the N-terminal region of SEMA6D (1:1200; ab198745; Abcam; Cam-
bridge, UK) or rabbit monoclonal antibody against β-actin (1:2000 4970S; Cell Signalling
Technologies; Beverly, MA, USA) in TBST/3% non-fat milk overnight (4 ◦C), and then with
HRP-tagged secondary antibody (Cell Signalling Technologies; Beverly, MA, USA) (1:4000
in TBST, 3 h, room temperature). Blots were visualized using Pierce ECL reagents (Ther-
moFisher, Waltham, MA, USA) by ChemiDoc (BioRad; Watford, UK), and densitometry
was performed using ImageJ (NIH Freeware, Bethesda, MD, USA).
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2.6. Biotinylated miRNA Mimic Pulldowns, RNA-seq, and Data Analysis
Transfected MCF7 cells were harvested with trypsin-EDTA 24 h post-transfection,
washed with PBS, collected by centrifugation (400× g, 5 min) and resuspended in ice-
cold 1.5 mL lysis buffer (20 mM Tris pH7.5, 200 mM NaCl, 2.5 mM MgCl2, 0.05% Igepal,
1 mM PMSF, 1 mM DTT, 60U Superase-In RNase Inhibitor (ThermoFisher; Waltham, MA,
USA)). Following cell lysis, samples were centrifuged (12,000 g, 15 min, 4 ◦C). Supernatants
(excepting 50 µL aliquots that were kept as input samples) were added to pre-blocked
Pierce High Capacity Streptavidin Agarose beads (ThermoFisher; Waltham, MA, USA)
and incubated for 4 h at 4 ◦C whilst rotating. Beads were then washed with ice-cold
lysis buffer. Total RNA was extracted using TRI-Reagent (Sigma; St Louis, MO, USA)
following the manufacturer’s protocol. The aqueous phase was separated, and 5 µL
GlycoBlue Coprecipitant (ThermoFisher; Waltham, MA, USA) was added before ethanol
precipitation at −80 ◦C overnight. RNA was collected, washed, and resuspended in
nuclease-free water. Total RNA samples were depleted of rRNA using Ribo-Zero Gold
rRNA Removal Kits (Illumina; San Diego, CA, USA) according to the manufacturer’s
instructions. Libraries were prepared using TruSeq Stranded Total RNA (Illumina; San
Diego, CA, USA) reagents and protocols. Samples were quantified using Quanti-iTTM High
Sensitivity dsDNA Assay Kits and the Qubit®2.0 Fluorometer (Thermofisher; Waltham,
MA, USA) and quality was assessed using the TapeStation 2200 and High Sensitivity D1000
ScreenTape (Agilent; Santa Clara, CA, USA). A total of 6 samples (pulldown: control, 195,
26b; input: control, 195, 26b) were sequenced in a single lane of paired-end sequencing
using the HiSeq 3000 (Illumina; San Diego, CA, USA). Sequencing data (FASTQ) are
available at the Sequence Read Archive (Available online: https://www.ncbi.nlm.nih.gov/
sra) with the BioProject ID PRJNA725393. FASTQ files were aligned to the GRCh38 version
of the human genome with STAR [25], using the two pass method that permits higher
sensitivity of novel splice junction detection [26]. Header and read groups were then
manually added to SAM files using Picard Tools (Broad Institute; Cambridge, MA, USA) to
label individual samples. Data quality control was performed using FastQC (Babraham
Institute; Cambridge, UK) before and after the removal of adapter sequences, primers
and polyA tails using Cutadapt [27]; all samples passed quality control. Read counts
were normalized to total reads per sample, and differential expression/pulldown was
determined using DESeq (EMBL; Heidelberg, Germany).
2.7. Data Mining
The starBase resource (v2) [28,29] was available online: https://bio.tools/starbase
and mRNAs with potential binding sites for miR-195 or miR-26b were identified using
default settings. METABRIC data were accessed using cbioportal [30], as reported previ-
ously [31]. Records with SEMA6D expression data and suitable clinical annotation were
identified (n = 1979; of these, n = 412 annotated as treated with cytotoxic chemotherapy
for primary disease and n = 1567 annotated with sufficient treatment details to make clear
cytotoxic chemotherapy was not used for primary disease; this does not include cases
where treatment details were simply missing). A table summarizing the clinico-patholgical
features of this cohort is shown as Table S2. Cases were dichotimised into low and high
SEMA6D using arbitrary cut offs: ”low” was levels below −0.82 SD from the mean for the
DFS analyses, or below −0.75 SD from the mean for the DSS analyses.
2.8. Statistical Analyses
Statistical analyses were performed using Prism (GraphPad, San Diego, CA, USA)
using tests indicated in figure legends. p < 0.05 was taken to indicate significance.
3. Results
3.1. MiR-195 and miR-26b Expressions Were Consistently Changed Post-NAC
Our first aim was to identify miRNAs that were consistently differentially expressed
in breast cancer cells between matched pre- and post-NAC samples, our hypothesis being
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that expression changes in cells surviving therapy are associated with relative therapy
resistance. We focused on estrogen receptor positive/HER2 negative breast cancers treated
with a specific chemotherapy regimen (epirubicin/cyclophosphamide) in order to reduce
sample heterogeneity. This strategy also aided analysis of post-NAC cells, since estrogen
receptor positive breast cancers are relatively resistant to chemotherapy as compared to
other breast cancer subtypes [22], therefore increased numbers of post-therapy cells would
be present.
We identified a cohort of 5 suitable cases demonstrating partial NAC resistance, and
for which pre- and post-therapy tissues were available. Epithelial breast cancer cells were
purified from tissues by laser capture microdissection to ensure that the changes identified
were associated with differential expression in cancer cells, rather than potentially with
changes in tissue composition, as are known to be induced by neoadjuvant therapy [32].
We have published representative images of this microdissection previously [6]. RNA
was extracted from purified cells and the relative expression of 377 miRNAs was assessed
using qPCR arrays. A total of 12 miRNAs were consistently differentially expressed
between matched samples from all 5 patients; the fold differences for these are shown for
all 5 patients, along with the mean fold change, in Table 1. A total of 10 miRNAs were up-
regulated after treatment, while only 2 were down-regulated. We excluded 10 from further
study by using the criterion of requiring an arbitrary minimum of 1.3-fold differential
expression in every tumour, and subsequently focused on miR-195 and miR-26b, which
were consistently up-regulated post-NAC by means of 2.6- and 4.9-fold respectively.
Table 1. A total of 12 different miRNAs were consistently up-regulated or consistently down-
regulated in breast cancer cells after neoadjuvant chemotherapy in 5 cases of estrogen receptor
positive breast cancer. Cancer cells were isolated by laser capture microdissection from matched
samples of pre- and post-neoadjuvant chemotherapy (NAC) breast cancer tissue. qPCR arrays were
used to quantify the relative expression of 377 different microRNAs. Fold differences in post-NAC
expression relative to pre-NAC are shown for each cancer case, along with the mean fold difference.
* denotes fold differences that were estimated when the miR was not detected in one of the paired
samples; the estimation is based on defining expression in this sample as the theoretical limit of
detection (i.e., a cycle threshold of 40); these estimates were excluded from the assessment of mean
fold differences.
MiRNA Case 1 Case 2 Case 3 Case 4 Case 5 Mean
miR-195 3.46 1.84 1.70 1.33 4.50 2.57
miR-26b 3.39 1.54 1.92 1.79 15.7 4.87
let-7c 1.71 2.76 1.99 1.15 1.94 1.91
miR-10a −2.33 −1.42 −14.4 −1.27 −1.36 −1.83
miR-26a 1.72 1.18 2.83 1.54 2.69 1.99
miR-330 1.70 1.32 1.11 1.82 >30 * 1.49
miR-335 3.15 4.94 1.16 1.55 >120 * 2.70
miR-362 1.68 1.03 1.27 2.85 >100 * 1.71
miR-483-5p 7020 3.34 1.13 2.27 19.9 1410
miR-885-5p >870 * 1.14 42.0 2.69 >20 * 15.29
miR-625 27.8 1.24 1.10 4.04 >10 * 8.53
miR-365 −1.18 −1.47 −4.03 −1.19 −1.66 −1.55
3.2. Altered Expression of miR-195 or miR-26b Controls Chemoresponse in ER Positive Breast
Cancer Cell Lines
Next, we aimed to assess whether miR-195 or miR-26b were capable of directly
modulating chemoresponse in breast cancer cells. Therefore, we transfected two separate
breast cancer cell lines with either miRNA mimics to up-regulate expression, or miRNA
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inhibitors to down-regulate expression, and assessed the impact on chemosensitivity. We
used MCF7 and MDA-MB-175 cells, since these are representative of the same breast
cancer molecular subtype (estrogen receptor positive/HER2 negative) as our initial patient
cohort. First, we transiently transfected each cell type with mimics of miR-195 or miR-26b,
scrambled control mimics, or with miR-195 or miR-26b targeted or control miR inhibitors,
and performed qPCR to assess the extents of up- or down-regulation (Figure 1A). We
concluded that mimics allowed up-regulation by at least 144-fold, while inhibitors caused
more modest down-regulation of 6- to 10-fold, although for miR-195 in the MDA-MB-175
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Figure 1. Increased miR-195 and miR-26b ex r es che oresistance in estrogen rec ptor positive breast can er
cells. The MCF7 or MDA-MB-175 ce ls were tr ith iRNA mimics or mimic ontrols (195, 26b or con) or miRNA
inhibitors or inhibitor control (i195, i26b r i ). ( ) after transfection, qPCR was performed to assess the relative
expression of miR-195 or miR-26b as appropriate. ata represent 1 biological experiment, with SD of technical triplicates.
(B,C) 48 h after transfection, cells were treated with either two doses of epirubicin as indicated or with the vehicle control.
Relative survival was determined using MTT assays 24 h later. Data are presented in two separate plots: left, relative
to untreated (vehicle control), with 1 biological repeat showing error bars representing the SD of 3 replicate wells; right,
relative to mimic controls, representative of means of 3 (MCF7) or 2 (MDA-MB-175) biological replicates, with error bars
representing the SEM of biological replicates. Differences between the targeted mimic and mimic controls were tested using
paired 1-tailed t tests; * indicates p < 0.05.
Having confirmed that we could experimentally manipulate levels of miR-195 and
miR-26b, we next tested their impacts on chemoresponse to epirubicin, since this was
the key cytotoxic agent with which the patients were treated, and is representative of the
anthracycline family of chemotherapeutics, which are a component of the vast majority
of chemotherapy regimens for primary breast cancer. Cells were transfected with mimics,
inhibitors or controls as above, and were then treated with one of two doses of epirubicin,
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equating to ~IC25 and ~IC75 doses for each cell line, or with vehicle control. It was notable
that MDA-MB-175 cells were intrinsically substantially more resistant to epirubicin than
MCF7 cells, a fact we believe may relate to their lower growth rate. Cell survival was
assessed using MTT assays. Survival is shown relative to the vehicle control in the left plots,
while survival after transfection with the targeted mimic or inhibitor is shown relative to
the scrambled control in the right plots (Figure 1B,C and Figure S1). The MiR-195 mimics
induced significant increases in survival after treatment with the lower epirubicin dose in
MCF7 cells (p < 0.05) and the higher dose in MDA-MB-175 (p = 0.05), with similar trends
visible at the other doses (Figure 1B). The MiR-26b mimics induced significant increases in
survival after treatment with both doses in MCF7 cells, and the higher dose in MDA-MB-
175 cells (Figure 1C; p < 0.01). The inhibitors, however, had no significant influences on
survival (Figure S1).
In addition, we assessed epirubicin sensitivity after the manipulation of miRNA
expression using clonogenic survival assays, in which cells were treated with the drug
and then cultured at relatively low cell density in fresh medium without the drug for
two weeks to allow a measurement of the proportions of cells that retained long-term
proliferative ability. This assay is very sensitive to cellular damage that does not cause
immediate short-term death, as detected by our MTT-based assay, but is nevertheless
damage that compromises the replicative potential of the cells. Consequently, this assay
is more reflective of some aspects of clinical cancer treatments where the key aim is to
avoid cancer regrowth. Importantly, much lower drug doses were used in this clonogenic
assay, reflecting the greater sensitivity to cellular damage. Cells were transfected as before,
and then treated with the vehicle control or epirubicin at doses equating to ~IC50 for
this assay, and clonogenic survival was determined; data are again presented relative to
vehicle control (left) or relative to control mimics/inhibitors (right) (Figure 2). The MiR-
195 mimics caused significant increases in survival in both cell lines (p < 0.05), while the
miR-26b mimics showed similar effects, although significant in only the MDA-MB-175 cells
(Figure 2A). By contrast with the MTT results, the miR-195 inhibitors caused significantly
decreased survival in both cells (p < 0.02), as did the miR-26b inhibitors in the MDA-MB-175
cells (p < 0.03) (Figure 2B).
We also developed an epirubicin-resistant model system by continuous culture of
MCF7 cells in increasing doses of epirubicin. The resistant cells (R) showed an IC50 of ~25
µM as compared to ~2 µM in the parental wildtype cells (WT) (Figure S2A). As a further
test of the potential roles of miR-195 and miR-26b, we examined the expression of these
miRNAs in both lines. We observed that miR-195 and miR-26b were up-regulated in the
resistant line as compared to parental line (Figure S2B).
We concluded that miR-195 or miR-26b were regulators of response to epirubicin, with
increased expression associated with relative resistance, as predicted from our assessment
of patient samples (Table 1).
3.3. SEMA6D Is a Candidate Target of miR-195 and miR-26b
Having identified miR-195 and miR-26b as contributing to chemoresistance, our next
aim was to identify target(s) of these miRNAs that contribute to this phenotype. Many
methods have been reported for the identification of miRNA targets, however each is
associated with a substantial false positive rate and there is no consensus for which is most
effective [33]. In addition, miRNAs can target different genes in different cell types [34],
a factor solely bioinformatics-based target prediction is unable to consider. We therefore
combined methods, including both the most common computational prediction and a
much more rarely performed biochemical pulldown approach, using our cell type of
interest [35,36].
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Figure 2. MiR-195 and miR-26b modify the chemoresponse of estrogen receptor positive breast cancer cells. The MCF7 or
MDA-MB-175 cells were transfected with miRNA mi ics or i ic controls (A) or miRNA inhibitors or inhibitor controls
(B) (195, 26b or con (c)). 48 h after transfection, cells were treated with epirubicin (“+”; MCF7 30 nM; MDA-MB-175 600 nM)
or it vehicle control (“−”). 24 h later, cells were replated at low density in fresh medium in or er to determine relative
survival in colony f rming assays. Dat are presented in two separate pl ts: left, relative to untreated ( ehicle control), with
1 biological repeat showing error bars representing SD of 2 replicate wells; right, r lative to mimic or inhibitor contr ls,
rep esentativ of means f 3 (MCF7) or 2 (MDA-MB-175) biological replicates, with error bars representing the SEM of
biological repli tes. Differ nces between targeted mimic/inhibitor and controls were tested u ing pair d 1-tailed t tests;
* indicates p < 0.05.
For computational predictions of miRNA targets, we used the on-line resource star-
Base [28,29], which gathers data from five commonly used predictive algorithms (miRanda,
PicTar, TargetScan, RNA22 and PITA). A total of 55 and 24 genes were predicted as targets
by all five algorithms for miR-195 and miR-26b respectively (Table S3). Next, we used
an experimental approach; the MCF7 cells were transfected with biotin-tagged miR-195
or iR-26b m mics, or scrambl d cont ols, with a view to using these mimics as baits to
pull down mRNA targets for identific tio by RNA-seq. First, we checked that biotin tags
did not interfere with miRNA function by confirming that tagged mimics continued to
confer chemoresistance to MCF7 cells after transfection (Figure S3). Next, we transfected
MCF7 cells, recovered tagged mimics on streptavidin beads, and sequenced RNA that
was associated with these pulldowns. We identified mRNAs that were at least 100-fold
over-represented in the miR-195 or miR-26b pulldowns as compared to the scrambled
control pulldown, thereby defining transcripts representing 787 genes as potential targets
of miR-195, and 787 genes (by chance, exactly the same number) as potential targ ts of
miR-26b (Table S3).
Finally, we noted the genes that had been identified in both the computational predic-
tions above and in our experimental pull-down as the strongest candidates: for miR-195,
we were left with only one gene, SEMA6D, while for miR-26b we were left with none. We
next tried a less stringent computational strategy by including genes predicted by only four
of the five algorithms; in this case, the intersection between computational predictions and
experimental candidates was SEMA6D and HOXA10 for miR-195, and SEMA6D (again)
and HOXC4 for miR-26b. Therefore, we proceeded with SEMA6D as our key candidate
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downstream mediator of chemoresistance. The predicted binding sites for these miRNAs
on the SEMA6D transcript are shown in Figure S4.
3.4. SEMA6D Is Targeted by miR-195 and Mediates Chemoresistance In Vitro
Next, we assessed whether SEMA6D is a downstream target of our chemoresistance-
related miRNA, focusing on miR-195 since SEMA6D was the only consistently predicted
target for this miRNA. We transiently transfected MCF7 cells with miR-195 mimics or
inhibitors, or controls, as before, and assessed the relative SEMA6D mRNA expression
by qPCR (Figure 3A). In accordance with SEMA6D being a target of miR-195, expression
of SEMA6D was significantly increased when miR-195 was inhibited (p < 0.0001), and
showed a trend towards being decreased by miR-195 mimics. In support of this, SEMA6D
expression was also decreased in our epirubicin-resistant MCF7 cell line (Figure S5), in
which we had previously noted increased expression of miR-195. We concluded that
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Figure 3. SEMA6D is a target of miR-195 and modifies chemoresponse. (A) The MCF7 cells
were transfected with miR-195 i ics, inhibitors or controls. Relative SEMA6D expression was
determined 72 h after transfection by qPCR. Data represent means (+/−SEM) of two biological
repeats. Differences between targeted mimic/inhibitor and appropriate control were tested using
paired 1-tailed t tests; * indicates p < 0.05. (B) The MCF7 cells were transfected with siRNA
targeted against SEMA6D or the scrambled control. Proteins were extracted after 72 h and Western
blots were performed for SEMA6D or actin (loading control). Relative SEMA6D expression was
quantified using densitometry. Data represent 2 independent biological experiments (mean +/−
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SEM). (C,D) The MCF7 cells were transfected with siRNA targeted against SEMA6D or the scrambled
control and treated with doses of epirubicin as indicated, or with vehicle control. Relative survival
was determined using MTT (C) or colony forming assays (D). Data are presented in two separate plots:
left, relative to untreated (vehicle control), with 1 biological repeat showing error bars representing
the SD of replicate wells; right, relative to siRNA controls, representative of means of 2 (panel C)
or 3 (panel D) biological replicates, with error bars representing the SEM of biological replicates.
Differences between targeted siRNA and control were tested using paired 1-tailed t tests; * indicates
p < 0.05.
Our next aim was to test whether SEMA6D expression directly influenced chemore-
sponse in accordance with a function downstream of miR-195. We transiently transfected
MCF7 cells with siRNAs targeting SEMA6D or a non-targeting control and confirmed that
the siRNA effectively knocked-down SEMA6D expression. The SEMA6D was expressed
as two specific protein species, as detected by an antibody recognizing the N-terminus;
expression of both was reduced by the targeted siRNAs (Figure 3B). Then, we repeated
these transfections and assessed sensitivity to epirubicin as previously, using either MTT
assays (Figure 3C) or clonogenic survival assays (Figure 3D). Cells with reduced expression
of SEMA6D were significantly more resistant to epirubicin both at the lower dose for the
MTT assays (p < 0.05) and in the clonogenic survival assays (p < 0.01). We concluded
that reduced SEMA6D expression caused relative epirubicin resistance, and therefore that
miR-195 mediates chemoresponse, at least in part, through SEMA6D.
3.5. SEMA6D Is a Predictive Marker of Chemotherapy Response in Breast Cancer Patients
Having implicated SEMA6D expression in defining the chemoresponse of breast
cancer cells, we next examined whether levels of SEMA6D would predict survival in breast
cancer patients after chemotherapy. We accessed transcriptome and survival data for
primary breast cancer cases from the METABRIC study [37], and tested whether SEMA6D
expression levels correlated with either disease-free survival or disease-specific survival in
these breast cancer cases (n = 1979; Figure 4A). Importantly, we also separated the cases into
those who received chemotherapy for primary disease and those who did not (Figure 4B).
We found that SEMA6D expression did not significantly impact disease-free survival in
the complete cohort (Figure 4A top panel), although low expression was significantly
correlated with disease specific survival (p = 0.005; Figure 4A bottom panel). Importantly,
low expression significantly correlated with reduced disease-free and disease-specific
survival in patients treated with chemotherapy (p = 0.009 and p = 0.004 respectively), but
not in those treated without chemotherapy (Figure 4B). Furthermore, we also analysed
whether receptor status impacted the predictive value of SEMA6D expression. Patients
treated with chemotherapy were additionally subdivided into estrogen receptor positive or
negative cases, and HER2 positive or negative cases, and separate Kaplan–Meier analyses
were performed (Figure S6). Despite relatively low numbers of cases and/or events in
these subgroups, significant predictive value for SEMA6D expression was maintained
in the estrogen receptor negative subgroup (p = 0.017) and the HER2 positive subgroup
(p = 0.022). We concluded that SEMA6D is a predictive marker of poor response, specifically
to chemotherapy, with low expression allowing the identification of a group of patients
prone to suffering very early recurrences after chemotherapy (inside 24 months).
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Figure 4. Low SEMA6D expression predicts poor survival in breast cancer patients specifically after hemotherapy.
METABRIC transcriptomic data for breast cancers were accessed via cbioportal and records with SEMA6D expression data
and suitable clinical annotation were identified (n = 1979). Kaplan–Meier survival analyses for disease-free survival (DFS;
top plots) or disease–specific survival (DSS; bottom plots) were performed, comparing the relatively low and high SEMA6D
expression groups within the full cohorts (A) or within those treated with chemotherapy (B left plots; n = 412) and those
treated without (B right plots; n = 1567). Significance was assessed using Log Rank tests.
4. Conclusions
We present the first examination of miRNA expression changes after clinical chemother-
apy, specifically within breast cancer cells. We found only 12 miRNAs to show consistent
expression changes, and fold changes were relatively small (<5-fold; Tables 1 and S1). Pre-
viously, a much larger number of miRNAs have been identified as differentially expressed
in breast tissues after chemotherapy; Lindholm et al. showed significant differences in
251 miRNAs [12], although this was based on differences in distributions of expression
levels pre- and post-therapy, in contrast to our analysis that demanded consistent directions
of differential expression between the matched samples in every case. As for the magnitude
of differential expression, our data are typical, with other reports showing miRNAs to be
differentially expressed mainly by 2- to 8-fold [12,14]. It should be noted that it is well-
established that relatively small changes in miRNA expression can have substantial impacts
on downstream functions [38]. Interestingly, miR-195 was previously reported as signifi-
cantly up-regulated after chemotherapy in breast cancer, supporting our data, although
our finding for miR-26b was not reproduced [12]. The critical difference between our study
and previous reports is that we have focused on the cancer cells themselves, isolated by
laser microdissection, thereby avoiding the confounding factor of chemotherapy-induced
changes in the cellular constituents of tissues [17,19]. We believe this may explain the
notable lack of consistency in published findings, represented by the facts that no single
miRNA has had differential expression consistently demonstrated [12–16], and that only
one miRNA identified in this way has previously been functionally validated successfully
as a chemoresponse modulator (miR-18a [13], although its differential expression was not
reproduced here or elsewhere [12]).
We have identified and validated two miRNAs, miR-195 and miR-26b, that function-
ally impact chemosensitivity in breast cancer cells (Figures 1 and 2). MiR-195 has been
studied extensively in breast cancer previously, mainly as a circulating biomarker for breast
cancer diagnosis or prognosis [39,40]. Interestingly, higher circulating miR-195 was found
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to correlate with poor responses to neoadjuvant chemotherapy [40], which is concordant
with our observation that higher cellular levels are associated with chemoresistance, al-
though it is uncertain whether circulating miR-195 derives even in part from the cancer
cells. This may, however, be a reasonable assumption, since miR-195 has been shown
to be contained in breast cancer cell-derived extracellular vesicles, secretion of which in-
creased on chemotherapy treatment, thereby inducing chemoresistant features in vitro and
in mouse models [41]. More generally, miR-195 is thought to be a tumour suppressor in
breast cancer, with lower expression in cancer as compared to normal tissues and ectopic
expression associated with reduced proliferation and invasion [42]. MiR-26b is less well
studied than miR-195 in the context of breast cancer, although, like miR-195, reports indi-
cate down-regulation in cancers and an anti-proliferative role in over-expression [43,44].
A range of targets have been reported for either miR-195 or miR-26b in various contexts.
However, since miRNA-mRNA pairings can differ depending on cell type [34], we wished
to determine targets experimentally by using the cells in which we had noted their chemore-
sistance function. Therefore, we identified mRNAs bound to biotin-tagged miRNA mimics
within cells using RNA-seq [36]. This technique is increasingly common, particularly in
the context of assessing the lncRNA-miRNA interactions which are likely to be relatively
stable and therefore experimentally more amenable [45], but has not previously been at-
tempted for either miR-195 or miR-26b. To our surprise, through this and the prediction of
miRNA binding sites, we identified the same shared target for both our miRNAs, namely
semaphorin A6D (SEMA6D).
Dysregulation of semaphorins, a family of 20 related genes, is well established in can-
cer, and they are emerging as biomarkers and therapeutic targets [46], but relatively little is
known specifically about SEMA6D in cancer. The family consists of trans-membrane pro-
teins that act in cell-to-cell signalling through interactions with plexin receptors, working
both very locally in full-length trans-membrane form or as secreted ligands when released
through the proteolytic cleavage of ectodomains [46]. SEMA6D has been associated with
a number of developmental roles, including cardiac morphogenesis [47], T-cell prolifera-
tion [48], and axonal guidance [49], functioning either as a ligand signaling through plexins
(typically plexA1) or as a signal-transducing receptor itself. In the context of breast cancer,
relatively high SEMA6D tissue expression has been associated with improved survival,
particularly in the triple negative subtype that is invariably treated with chemotherapy [50];
this is compatible with our findings, although we fine-tune the observation to report im-
proved survival as occurring only after chemotherapy (Figure 4). The other published
finding concerning breast cancer is that the somatic SEMA6D mutations that were pre-
dicted to cause loss of gene function were identified in early onset breast cancers [51], a
cancer type that is typically aggressive, frequently triple-negative, and associated with
poor outcomes; this result, again, is potentially compatible with our finding that lower
SEMA6D expression was associated with poorer outcomes. Some support is also available
from other cancers; for example, in lung cancer, which is also invariably treated with
cytotoxic chemotherapy, somatic SEMA6D mutations were found that reduced SEMA6D
expression, and low SEMA6D expression was associated with poor outcomes [52]. In
terms of mechanisms, it is challenging to speculate since it has not even been determined
in these cells whether SEMA6D is working as a ligand for plexins, or as a receptor in its
own right, therefore a multitude of potential down-stream signaling pathways exist [46].
However, there are potentially differences between different cancer types since higher
SEMA6D expression was linked with chemotherapy resistance in osteosarcoma [53], albeit
that this was resistance to cisplatin, which is a different class of chemotherapy agent. It
should be noted that epirubicin (an anthracycline), the key chemotherapy agent in our
study, acts by intercalating with DNA and also by inhibiting topoisomerase function [54],
while the platinum-based agents, of which cisplatin is an example, act by inducing DNA
base-adducts [55]. Nevertheless, our findings raise the prospect of attempting to manipu-
late semaphorin signalling to improve chemotherapy responses in breast cancer, and the
potential of agonists for this pathway, or even using secreted semaphorins themselves as
Cancers 2021, 13, 5979 14 of 16
therapeutics has been explored previously in breast cancer [56] and other contexts [57],
although not in combination with cytotoxic chemotherapy.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/cancers13235979/s1, Figure S1: Reduced miR-195 and miR-26b expression has little consistent
impact on chemoresponse in estrogen receptor positive breast cancer cells as assessed by MTT assays.
Figure S2: MiR-195 and miR-26b are overexpressed in a epirubicin-resistant cell line. Figure S3: Biotin-
tagged miR-195 and miR-26b mimics induce chemoresistance in MCF7 cells. Figure S4: Predicted
binding sites for miR-195 and miR-26b in the 3’ untranslated region of the SEMA6D transcript.
Figure S5: SEMA6D expression was significantly reduced in epirubicin-resistant MCF7 cells as
compared to parental. Figure S6: Low SEMA6D expression predicts poor survival in patients with
estrogen receptor negative cancers and with HER2 positive cancers. Table S1: Clinico-pathological
features of the discovery breast cancer cohort (n = 5; all estrogen receptor positive / HER2 negative).
Table S2: Clinico-pathological features of the validation breast cancer cohort (n = 1979).
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